IAG
Government Contracts & Awards
Proprietary Tech & Patents
ANTI-CSF-IR ANTIBODY
LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS
COMPOSITIONS AND METHODS FOR DETECTING PLASMODIUM SPECIES NUCLEIC ACID
Compositions and Methods for Nucleic Acid Quality Determination
Form D Funding
Private Placement
Private Placement
Market Intelligence & News
Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...
OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
RAHWAY, N.J., July 24, 2026--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results
Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a buy.
Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary
Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Quest Diagnostics Inc (DGX) reports robust financial performance with a 10% revenue increase, while navigating operational headwinds and strategic investments.
Key People
No individuals linked to this entity yet.
Political Giving
$263,455 given to 60 candidates across 168 disclosed contributions (FEC Schedule A).
Scott H. Peters
Lori Trahan
Gus M. Bilirakis
Nanette Barragan
Darin McKay LaHood
Earl Leroy Carter
Bradley S. Schneider
John Cornyn
Kim Schrier
Neal Patrick Dunn, MD, FACS
Adrian Smith
Thomas H. Kean
James E Hon Banks
Ron Wyden
Rudy C. Yakym
Frank Pallone
Terri A. Sewell
Elizabeth Fletcher
Linda T. Sanchez
Suzan K. DelBene
+ 40 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro